Could Tilray (TLRY) Expanding Into Panama Reveal Its Strategy for International Medical Cannabis Leadership?

• Earlier this month, Tilray Medical announced its entry into Panama's medical cannabis market through a joint venture with Top Tech Global Inc., securing a license for cultivation, manufacturing, and distribution of medical cannabis products.
• This expansion highlights Tilray's ongoing commitment to global market growth and underscores its focus on enhancing patient access to cannabinoid-based therapies in new regions.
• We'll explore how Tilray's push into Panama may strengthen its international footprint and help shape the company's investment outlook.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 35 best rare earth metal stocks of the very few that mine this essential strategic resource.

Tilray Brands Investment Narrative Recap

To be a shareholder in Tilray Brands, you have to believe in the long-term potential of global cannabis market expansion and diversified product innovation, set against persistent operational losses and slow U.S. legalization efforts. The Panama medical cannabis joint venture reinforces Tilray’s international ambitions but does not materially change the core, near-term catalyst: regulatory progress in key markets, especially the United States, nor does it mitigate the ongoing risks tied to profitability and cash flow.

One of Tilray’s latest brand launches, Redhook 81 light lager, speaks to its push in diversifying revenue through beverages. While this supports broader ambitions, soft industry beer demand and past beverage headwinds remind investors why the company’s biggest catalyst remains unlocking meaningful new cannabis markets, not incremental alcohol launches.

However, just as international ventures shine a light on growth, investors should not ignore the ongoing threat of persistent losses and...

Read the full narrative on Tilray Brands (it's free!)

Tilray Brands' narrative projects $940.4 million in revenue and $193.4 million in earnings by 2028. This requires 4.6% yearly revenue growth and an increase in earnings of about $2.4 billion from current earnings of $-2.2 billion.

Uncover how Tilray Brands' forecasts yield a $1.78 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Nineteen members of the Simply Wall St Community peg Tilray’s fair value from US$1.14 to US$8.04 per share. Against this wide spread, remember sluggish US cannabis reform continues to influence the company’s overall performance and investor optimism can diverge greatly.

Explore 19 other fair value estimates on Tilray Brands - why the stock might be worth over 5x more than the current price!

Build Your Own Tilray Brands Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tilray Brands research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free Tilray Brands research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tilray Brands' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com